AstraZeneca’s new head of Investor Relations, Joris Silon, succeeds Andy Barnett on 1 March 2026, and will be based in ...

Why AstraZeneca is on investors’ radar today AstraZeneca (LSE:AZN) has been drawing attention after a period of solid share price gains. This is prompting investors to reassess how its current ...

If you are wondering whether AstraZeneca shares still offer fair value after a strong run, or if you might be paying too much for the story, this article is designed to help you frame that question ...

Positive full results from the Phase III TULIP-SC trial showed the subcutaneous administration of Saphnelo demonstrated a statistically ...

In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...

BostonGene, the developer of an AI foundation model for tumor and immune biology, has entered a strategic collaboration with ...

On Jan. 4, 2021, a COVID-19 vaccine developed by AstraZeneca and Oxford University was administered for the first time, to an ...

While AstraZeneca has announced that it will participate in the 2026 JP Morgan Healthcare Conference, it hasn’t yet revealed details about its presentation.

US biotech BostonGene has struck a research collaboration with British pharma AstraZeneca (LSE: AZN) to explore the use of ...

AstraZeneca has delivered on CEO Pascal Soriot’s promise to grow revenues to more than $40 billion by 2023. Now, the chief exec is already mapping out his next goal. AZ’s global revenue in 2022 ...

AstraZeneca PLC AZN shares rallied 4.89% to £140.38 Tuesday, on what proved to be an all-around positive trading session for ...

AstraZeneca announces Saphnelo self-administration phase III TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in SLE disease activity: Cam ...